(Total Views: 413)
Posted On: 04/28/2021 7:16:26 PM
Post# of 1460
Copied from IHUB and is written by falconer66a,
Fletch
falconer66a Wednesday, 04/28/21 05:49:27 PM
Re: Steady_T post# 308463 0
Post # of 308470
Yes, a giant discriminator.
Quote:
[Safety] A property of 2-73 that is not to be underestimated. It is unlike anything else in the CNS drug space.
Exactly. To understand why Anavex 2-73 is safe is also to understand how it is so able to make neurons (and other cells) work normally, providing normal health.
Simply, the Anavex drug works in the CNS (central nervous system) like no other. Instead of trying to suppress or turn off the "downstream" symptoms of the various CNS diseases it will treat, by it's unique mechanism of action (MOA) it fixes bad neurology things at their very start; which is the neurons' inability to continue to function normally. With age, chemical inducements, injury, or bad genes, various self-control processes ("homeostasis"
in nerves and neurons fail to fully operate.
Conventional drugs, such as those new ones targeting the protein wastes that cause Alzheimer's disease (tau tangles, beta-amyloid deposits), work downstream from the real problem, after it's caused disease. Just the opposite for Anavex 2-73 (blarcamesine). By propitiously activating the sigma-1 receptor protein, that protein can then continue to chaperone and modulate a diversity of "downstream" processes; restoring their normal function. With that, as in youth or before Alzheimer's set in, neurons can continue to gather and destroy the pathogenic waste proteins (a function of blarcamesine's induced/restored autophagy).
Blarcamesine has no disqualifying side effects because it doesn't inadvertently disrupt any essential biochemical process. Just the opposite. It restores those processes (autophagy, homeostasis, protein folding, chromatin modulation, many others). Not the case, at all, with most nerve-acting drugs.
Anavex 2073 IS different. And it's owned by Anavex Life Sciences Corp.
https://investorshub.advfn.com/boards/read_ms...=163483653
Fletch
falconer66a Wednesday, 04/28/21 05:49:27 PM
Re: Steady_T post# 308463 0
Post # of 308470
Yes, a giant discriminator.
Quote:
[Safety] A property of 2-73 that is not to be underestimated. It is unlike anything else in the CNS drug space.
Exactly. To understand why Anavex 2-73 is safe is also to understand how it is so able to make neurons (and other cells) work normally, providing normal health.
Simply, the Anavex drug works in the CNS (central nervous system) like no other. Instead of trying to suppress or turn off the "downstream" symptoms of the various CNS diseases it will treat, by it's unique mechanism of action (MOA) it fixes bad neurology things at their very start; which is the neurons' inability to continue to function normally. With age, chemical inducements, injury, or bad genes, various self-control processes ("homeostasis"
in nerves and neurons fail to fully operate. Conventional drugs, such as those new ones targeting the protein wastes that cause Alzheimer's disease (tau tangles, beta-amyloid deposits), work downstream from the real problem, after it's caused disease. Just the opposite for Anavex 2-73 (blarcamesine). By propitiously activating the sigma-1 receptor protein, that protein can then continue to chaperone and modulate a diversity of "downstream" processes; restoring their normal function. With that, as in youth or before Alzheimer's set in, neurons can continue to gather and destroy the pathogenic waste proteins (a function of blarcamesine's induced/restored autophagy).
Blarcamesine has no disqualifying side effects because it doesn't inadvertently disrupt any essential biochemical process. Just the opposite. It restores those processes (autophagy, homeostasis, protein folding, chromatin modulation, many others). Not the case, at all, with most nerve-acting drugs.
Anavex 2073 IS different. And it's owned by Anavex Life Sciences Corp.
https://investorshub.advfn.com/boards/read_ms...=163483653
(2)
(0)Scroll down for more posts ▼
